Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $1.9 million.

  • Journey Medical's Share-based Compensation rose 1304.88% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 1223.09%. This contributed to the annual value of $6.1 million for FY2024, which is 13399.85% up from last year.
  • Journey Medical's Share-based Compensation amounted to $1.9 million in Q3 2025, which was up 1304.88% from $1.3 million recorded in Q2 2025.
  • Journey Medical's 5-year Share-based Compensation high stood at $2.4 million for Q4 2021, and its period low was $8000.0 during Q3 2021.
  • Over the past 5 years, Journey Medical's median Share-based Compensation value was $1.3 million (recorded in 2025), while the average stood at $1.1 million.
  • Per our database at Business Quant, Journey Medical's Share-based Compensation skyrocketed by 1787500.0% in 2022 and then crashed by 6326.39% in 2023.
  • Journey Medical's Share-based Compensation (Quarter) stood at $2.4 million in 2021, then plummeted by 40.62% to $1.4 million in 2022, then plummeted by 63.26% to $529000.0 in 2023, then skyrocketed by 160.49% to $1.4 million in 2024, then soared by 34.54% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.